Results 11 to 20 of about 4,368 (201)

Optimizing Finerenone Therapy: A Comprehensive Review Using the “Finerenone Pentad” [PDF]

Indian Journal Of Clinical Practice, 2023
Chronic kidney disease (CKD) is a pressing global health concern, often intertwined with comorbid conditions such as type 2diabetes mellitus (T2DM) and cardiovascular complications. Managing CKD in T2DM patients requires a multifaceted approach,and emerging therapeutic options are increasingly essential.
null Dr SOURABH SHARMA, null Dr SANJAY KALRA   +1 more
openaire   +2 more sources

Finerenone: First Approval

Drugs, 2021
Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart failure (HF), including chronic HF (CHF).
James Frampton (9301141)
openaire   +3 more sources

Finerenone as an add-on treatment to conventional therapies for the patients with diabetic kidney disease

BMC Nephrology
Background Finerenone has been shown to exert renoprotective effects in patients with diabetic kidney disease. However, the effects of finerenone on proteinuria and serum potassium levels in patients already receiving renin–angiotensin system inhibitors ...
Satoshi Kidoguchi, Sugano Naoki, Yohei Suehiro, Takashi Yokoo   +3 more
doaj   +2 more sources

Role of L‐type Ca2+‐channels in the vasorelaxing response to finerenone in arteries of human visceral adipose tissue [PDF]

Physiological Reports
Inadequate blood supply to the expanding adipose tissue (AT) is involved in the unhealthy AT remodeling and cardiometabolic consequences of obesity. Because of the pathophysiological role of upregulated mineralocorticoid receptor (MR) signaling in the ...
Francesca Schinzari, Alessandro De Stefano, Giuseppe Sica, Marco Mettimano, Carmine Cardillo, Manfredi Tesauro   +5 more
doaj   +3 more sources

Potassium management with finerenone: Practical aspects [PDF]

Endocrinology, Diabetes & Metabolism, 2022
AbstractIntroductionFinerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favourable effects on cardiorenal outcomes in patients with mild‐to‐severe chronic kidney disease with increased albuminuria and type 2 diabetes.MethodsTwo large, randomized trials have evaluated the effects of finerenone on clinical outcomes.
Wanner, Christoph, Fioretto, Paola, Kovesdy, Csaba, Malyszko, Jolanta, Pecoits-Filho, Roberto, Schnell, Oliver, Rossignol, Patrick   +6 more
openaire   +6 more sources

Non-steroidal mineralocorticoid receptor antagonist finerenone inhibits peritoneal fibrosis induced by high-glucose dialysate via regulating enhancer of zeste homolog 2 (EZH2) expression

Renal Failure
Finerenone, a novel high-selective aldosterone receptor antagonist, exhibits powerful anti-inflammatory and antifibrotic effects in previous researches. The aim of our study was to investigate of it on peritoneal fibrosis.
Dandan Chen, Jianqiang Shu, Xinyu Zhang, Simeng Wang, Jingshu Sun, Nannan Chong, Zhikang Sun, Ying Xu, Qinglian Wang   +8 more
doaj   +2 more sources

Renin–angiotensin system blockade: Finerenone

Néphrologie & Thérapeutique, 2017
Finerenone is a novel selective nonsteroidal mineralocorticoid receptor antagonist. Results in preclinical studies showed that lower doses of finerenone were needed to achieve similar cardiorenal protective effects compared to both spironolactone and eplerenone and phase II studies in finerenone in patients with heart failure, type-2 diabetes mellitus ...
Ruilope Urioste, Luis Miguel, Tamargo, Juan   +1 more
openaire   +4 more sources

Finerenone Ameliorates High Glucose-Induced Podocytes Epithelial-Mesenchymal Transition Through the Regulation of Krüppel-Like Factor 5 in Diabetic Nephropathy [PDF]

Diabetes, Metabolic Syndrome and Obesity
Jianqiang Shu,1 Dandan Chen,1 Wenzhen Chen,2 Xinyu Zhang,1 Simeng Wang,1 Nannan Chong,3 Zhikang Sun,3 Qinglian Wang,3 Jingshu Sun,4 Ying Xu1 1Department of Nephrology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, People’s Republic ...
Shu J, Chen D, Chen W, Zhang X, Wang S, Chong N, Sun Z, Wang Q, Sun J, Xu Y   +9 more
doaj   +1 more source

Effect of Finerenone on Morbidity and Mortality in CKD

Journal of the American Society of Nephrology
Key Points In three trials, finerenone reduced a range of cardiovascular and kidney outcomes in persons with diabetes and CKD. Benefits of finerenone were ...
John W. Ostrominski, Gerasimos Filippatos, Brian L. Claggett, Zi Michael Miao, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Katja Rohwedder, Meike D. Brinker, Andrea Scalise, Patrick Schloemer, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Peter Rossing, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Rajiv Agarwal, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan   +23 more
openaire   +4 more sources

Finerenone in chronic kidney disease

Journal of Kidney Care
New trial evidence suggests that finerenone may slow kidney disease progression and reduce cardiovascular risk in people with non-diabetic chronic kidney disease, including those with glomerular disease. These findings raise the possibility of a broader future role for finerenone in nephrology practice.
Peter Ellis
openaire   +2 more sources